CoChat

Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes

Open access
Jack, Gwendolyne A, Avenatti, Eleonora, Kashyap, Sangeeta R, Sadhu, Archana R · 2025 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

Despite mounting evidence supporting the cardio-kidney benefits of sodium/glucose cotransporter 2 inhibitors (SGLT2i), significant disparities in their use exist among people with type 2 diabetes (T2D), cardiovascular, or kidney disease that reveals a significant disconnect between guidelines and practice. These discrepancies are particularly pronounced among women, minority races, and lower socioeconomic groups. These groups remain underrepresented in major cardiovascular trials, potentially leading to their exclusion from optimal therapies and increasing morbidity and mortality rates. This review aims to highlight disparities in the use of SGLT2i in populations with T2D, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease. It examines the factors that influence the prescription of SGLT2i within these populations and evaluates their downstream impact on clinical outcomes. Finally, the review summarizes recent clinical trial findings on strategies that enhance the adoption of SGLT2i and other cardioprotective agents through a multifaceted approach, aiming to improve real-world adoption for patients with T2D and/or cardiovascular and kidney diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaf301

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Drivers of disparities and strategies to overcome them in SGLT2i use. Several systemic factors contribute to disparities in SGLT2i use whereby women, racial and ethnic minoritized groups, individuals with unfavorable social determinants of health (such as lower socioeconomic status and lower education level), and individuals exposed to clinician biases are less likely to be prescribed SGLT2i than are their counterparts. Several potential patient-level, clinician-level, and system-level strategies have been proposed including mitigating cost of treatment, changing policies, increasing diversity in clinical trials, leveraging technology, integrating an interdisciplinary care model, increasing patient and clinician education and engagement in order to achieve equitable access, affordability, and adoption of SGLT2i with the goal of improved cardio-kidney-metabolic outcomes.
Figure 1. Drivers of disparities and strategies to overcome them in SGLT2i use. Several systemic factors contribute to disparities in SGLT2i use whereby women, racial and ethnic minoritized groups, individuals with unfavorable social determinants of health (such as lower socioeconomic status and lower education level), and individuals exposed to clinician biases are less likely to be prescribed SGLT2i than are their counterparts. Several potential patient-level, clinician-level, and system-level strategies have been proposed including mitigating cost of treatment, changing policies, increasing diversity in clinical trials, leveraging technology, integrating an interdisciplinary care model, increasing patient and clinician education and engagement in order to achieve equitable access, affordability, and adoption of SGLT2i with the goal of improved cardio-kidney-metabolic outcomes.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Research works printed but not linked: 3

  1. National Institutes of Health, 2024, Minority Health and Health Disparities Strategic Plan 2021–2025
  2. Healthy People 2030, 2024, Priority Areas: Social Determinants of Health
  3. Healthy People 2030, 2024, Building a Healthier Future for All

Cited by

See all 9

Metadata

Authors
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R.
Affiliations
  • Weill Cornell Medicine (US)
  • Houston Methodist (US)
Corresponding author
Sadhu, Archana R
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2025-05-27
Volume
110
Issue
9
Pages
e2852-e2863
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4410789150
Cited by
9
References
81
Citations by year
2026: 8 · 2025: 1
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Weill Cornell Medicine
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
SGLT2 inhibitors, type 2 diabetes, health disparities, cardiorenal protection, chronic kidney disease, heart failure, atherosclerotic cardiovascular disease, underrepresentation in clinical trials, women, racial minorities, socioeconomic status, prescribing patterns, guideline adherence
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Healthcare Disparities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/clinem/dgaf301
The paper
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025). Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.